Showing results for 
Search instead for 
Did you mean: 

BLOG: Does Immunotherapy work for Prostate Cancer

Community Manager
Community Manager
0 0 275


Does immunotherapy work for prostate cancer

Immunotherapies as a single agent have not been shown to be effective for treating advanced prostate cancer till now. In this research blog we will try find out why they are not effective and what the potential alternatives are. Numerous blogs in the past have addressed the concept of immunotherapy and the types available. The premise of immunotherapy is that it harnesses the body’s own immune system to target and kill off cancer cells. They can be administered intravenously or as a vaccine. Sipuleucel-T was one of the first FDA approved immunotherapies, a vaccine that showed only a 4-month overall survival benefit originally (IMPACT Trial) with subsequent trials showing no survival advantage (PROSTVAC Trial)1. Other agents are the PARP inhibitors (olaparib) and pembrolizumab. Immunotherapy has shown good results for cancers of the bladder, kidneys, lung and skin, but why not for prostate cancer?

Prostate cancer is considered a “cold” tumour and with an immunosuppressive tumour microenvironment2. The tumour microenvironment is what’s responsible for tumour survival, growth and spread. Under a microscope there is a very low infiltration rate of immunological cells called “T Cells”. This is thought to be due to the fact that the inside of the tumour is hypoxic (has relatively low oxygen levels)3. There is a low supply of micronutrients to sustain the immune cells in this milieu. Therefore, scientists can’t use the immune system to fight the cancer cells in the tumour. Another point to consider is that bone is the most common metastatic site, and it is often the case that bone metastases are far less responsive to immunotherapy than metastases situated in soft tissues. However, there are many other components to the immune system and other target areas that are being explored (immune-intensification and immune-modulation)4. There are cells of the immune system surrounding the tumour that result in growth of the tumour and these could be potential targets for new therapeutic agents as well2.

Immunotherapies are also being combined in trials to take advantage of tumour cell destruction through multiple pathways. Immunotherapy is also being combined with androgen deprivation therapy, conventional chemotherapy as well as radiation. These treatment modalities release neoantigens when tumour cells are killed making immunotherapy more effective4. It has also been combined with tumour vaccines.

The immune system’s response to immunotherapy also varies between individuals and tumours themselves. Tumours that show a low mutational burden are less likely to respond to treatment. Individualised genomic studies may need to be carried out and then based on predictive factors of response/resistance - treatments can be tailored accordingly. This is already done for those who have microsatellite instability or mismatch repair gene defects and receive pembrolizumab after disease has progressed on conventional treatments – early data shows a response rate of 40% in this subgroup5. Going forward an immunogenic classification needs to be developed based on genomic profiling and a scoring system created to guide future treatment6. New tumour markers other than PSA are required (e.g. PD-1) to monitor the effects of these treatments as well as novel imaging approaches such as specialised PET Scans.

Currently research is focusing on immunotherapy for advanced disease but perhaps in the future these treatments may be used for earlier disease. Genomic testing of localised prostate cancer could be utilised to determine which tumours will recur or metastasize at a later stage and immunotherapy treatment regime initiated at that point.



  1. Gulley JL et al. Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer. J Clin Oncol 2019; 37:1051–1061.
  2. Kwon JTW, Bryant RJ, Parkes EE. The tumour microenvironment and immune responses in prostate cancer patients. Endocr.-Relat. Cancer 2021;28: T95-T107.
  3. Venkatachalam S, McFarland TR, Agarwal N, Swami U. Immune Checkpoint Inhibitors in Prostate Cancer. Cancers 2021; 13: 2187.
  4. Handa et al. Immunotherapy in prostate cancer: current state and future perspectives. Ther Adv Urol 2020; 12: 1-20.
  5. Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Research 2019; 25: 3753–3758.
  6. Tsaur I, Brandt MP, Juengel E, Manceau C, Ploussard G. Immunotherapy in prostate cancer: new horizon of hurdles and hopes. World J Urol 2021: 39:1387-1403.







 About the Author

Kalli Spencer

MBBCh, FC Urol (SA), MMed (Urol), Dip.Couns (AIPC)

Kalli is an internationally renowned Urological Surgeon, specialising in oncology and robotic surgery. He trained and worked in South Africa, before relocating to Australia where he has worked at Macquarie University Hospital and Westmead Hospital. His passion for what he does extends beyond the operating room, through public health advocacy, education and community awareness of men’s health, cancer and sexuality.

Kalli has been involved with the Prostate Cancer Foundation of Australia for many years, advocating for improved cancer care and facilitating community prostate cancer support groups.


Help is Available

Prostate Cancer Specialist Telenursing Service:

If your life has been impacted by prostate cancer, our Specialist Telenursing Service is available to help. If you would like to reach out to the PCFA Prostate Cancer Specialist Telenurse Service for any questions you have about your prostate cancer experience, please phone 1800 22 00 99 Monday - Friday 9am - 5pm, Wednesday 10am-8pm (AEST).


Prostate Cancer Support Groups:

PCFA is proud to have a national network of affiliated support groups in each state and territory of Australia consisting of men and women who have a passion for assisting others who encounter prostate cancer. This network is made up of over 170 affiliated groups who meet locally to provide one-to-one support, giving a vision of life and hope after treatment. Call us on 1800 22 00 99 to find your local group.


MatesCONNECT Telephone-based peer support:

MatesCONNECT is a telephone-based peer support program for men affected by prostate cancer. If you’ve recently been diagnosed with prostate cancer, our MatesCONNECT service can connect you to a trained volunteer who understands what you’re going through. All of our volunteers have been through prostate cancer. Simply call us on 1800 22 00 99 to be connected with a volunteer.


Newly diagnosed? or need to find more information -Access the PCFA resources here!

House Rules

To help keep this community a welcoming, supportive and caring place we have put together a small list of dos and don'ts for you to think about when posting on our forum, research blog or video gallery. For further information please see our  terms and conditions.

Adhere to PCFA’s five core values of Integrity, Optimism, Compassion, Respect and Commitment.

Our online forum is for you to share experiences with others and does not contain specific medical, counselling or legal advice.  If you require professional advice specific to your individual circumstances we encourage you to see a medical professional, legal professional or counsellor.

No commercial or promotional activity. While members may share information about resources they have found helpful, the PCFA Online Community forum should not be used for the promotion of goods and services. This includes commercial entities passing themselves off as individuals and people who frequently post links to external health professionals or other services.

Be kind to each other - many people using the community are going through a difficult time. A few kind words can go a long way. Please welcome new posters – it can be very nerve-wracking to post on the forum for the first time.

If you or someone you know is suffering from mental health issues, such as depression or anxiety, we encourage you to seek assistance and contact Beyond Blue Tel:1300 224 636 or Lifeline Tel:13 11 14

Speak your mind freely, but please be sensitive to the feelings and experiences of others - you might not always agree, but you can agree to disagree in a peaceful manner.

Don't use offensive language -if a user is found to be using offensive language during their conversations the moderators reserve the right to edit the thread, without warning.

Don't use all capital letters in your posts - it's considered ‘shouting' online and it makes posts difficult to read.

Give each other the benefit of the doubt - please remember that it is all too easy for the tone and meaning of posts to be misinterpreted. Think carefully before replying to a discussion. it It is important to remember that things written rather than said can feel much stronger, so please bear this in mind when reading other people's messages.

Please respect the moderators - their job is to keep the forum safe and constructive so that everybody gets to have his or her fair say.

Stay on topic - try to focus on the original topic. In particular, don't change subject in the middle of an existing thread - just start a new thread.

Read what's already on the forum before posting - you may be repeating what others have already said or asked.

We want PCFA's Online Community to be a secure and helpful environment for all of the community. So please remember that by using PCFA's Online Community you are agreeing to follow our terms and conditions.